(415) 353-2318 (appts)
(415) 476-0659 (fax)

Box 0538, UCSF; San Francisco, CA 94143-0538

additional websites:

UCSF Physician Referral Directory

Melbourne University Medical School, Melbourne, Australia, M.B.B.S., 1972, Medicine
St. Vincent's Hospital Medical School, Melbourne, Australia, Medicine
Melbourne University, M.D., 1991, Medicine/Immunology

(from 121)

Peters M and Fauci AS. Selective activation of antigen-specific human B cells in recently immunized individuals by nonspecific factors in the absence of antigen. J Immunol 1983;130:678-680.

Peters M, Walling DM, Kelly K, Davis GL, Waggoner JG, and Hoofnagle JH. Immunologic effects of interferon-α in man: treatment with human recombinant interferon-α suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J Immunol 1986;137:3147-3152.

Peters M, Ambrus JL, Zheleznyak A, Walling D, and Hoofnagle JH. Effect of interferon-α on immunoglobulin synthesis by human B cells. J Immunol 1986;137:3153-3157.

Peters M, Walling DM, Waggoner J, Avigan MI, Sjogren M, and Hoofnagle JH. Immune effects of α-interferon in chronic liver disease. J Hepatol 3 (Suppl. 2): 1986;S283-S289.

Peters MG, Ambrus JL, Fauci AS, and Brown EJ. The Bb fragment of complement factor B acts as a B cell growth factor. J Exp Med 1988;168:1225-1235.

Peters MG, Secrist H, Anders KR, Nash GS, Rich SR, and MacDermott RP. Normal human intestinal B lymphocytes: increased activation compared with peripheral blood. J Clin Invest 1989;83:1827-1833.

Peters MG, Anders K, Nash GS, Zheleznyak A, and MacDermott RP. Activation of intestinal mononuclear cells. Inflammatory Bowel Disease: current status and future approach RP MacDermott, ed., New York: Elsevier Science, 1988;67-72.

Ambrus JL, Haneiwich S, Chesky L, McFarland P, Peters MG, and Engler RJ. Abnormal response to a human B cell growth factor in patients with common variable immunodeficiency. J Allergy & Clin Immunol 1991;87:1138-1149.

Secrist H, Holers VM, Levine A, Egan M, Nahn MH, Butch AW, and Peters M. Induction of IL-4 and IL-6 synthesis in vitro: variation in signaling requirements and kinetics are dependent on the anatomic source of the responding mononuclear cells. Regional Immunology 1991;3:341-348.

McCabe RP, Secrist H, Botney M, Egan M, and Peters MG. Cytokine mRNA expression in intestine from normal and inflammatory bowel disease patients. Clinical Immunology and Immunopathology 1993;66:52-58.

Secrist H, Egan M, and Peters MG. Tissue-specific regulation of IL-4 mRNA expression in human tonsil. J Immunol 1994;152:1120-1126.

McCabe RP, Carroll WL, Egan M, Cohn SM, and Peters M. Immunoglobulin variable region usage in human intestinal B lymphocytes. Clinical Immunology and Immunopathology 1994;71:240-245.

Clatch RJ, Krigman HR, Peters MG, and Zutter MM. Dysplastic haemopoiesis following orthotopic liver transplantation: comparison with similar changes in HIV infection and primary myelodysplasia. British J of Haematology 1994;88:685-692.

Malizia G, Brunt EM, Peters MG, Rizzo A, Broekelmann TJ, and McDonald JA. Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology 1995;108:145-156.

Okuyama, S, Rubin D, Woodley M, and Peters MG. Regional expression of murine intestinal immune cells in normal and isografted intestine. Cellular Immunology 1995;163:198-205.

Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, and Brown EJ. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Science 1995;108:3419-3425.

Okuyama S, Rubin D, Streeter PR, and Peters M. Murine isograft studies of gut immunity: recirculation and homing of mononuclear cells. Gastroenterology 1997;112:1241-1249.

Peters MG. Guest Editor: Cytokines in liver injury and repair. Seminars in Liver Disease 1999;19:2.

Vierling JM, Teperman LW, Lake JR, Perrillo RP, Peters M, Fried M, Schiff ER. Case studies of the hepatitis B patient: A panel discussion. Seminars in Liver Disease 1999;19:S2:29-35.

Bodó I, Peters M, Radich JP, Hess J, Blinder M, Watson MS, Van Rheeden R, Natarajan S, Lowell JA, Brown R, DiPersio J, and Adkins D. Donor-derived acute promyelocytic leukemia in a liver-transplant recipient. N Eng J Med 1999;341:807-13.

Combes B, Carithers RL, Maddrey WC, Munoz S, Garcia-Tsao G, Bonner GF, Boyer JL, Luketic VA, Shiffman ML, Peters MG, White H, Zetterman RK, Risser R, Rossi SS, and Hofmann AF. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1999;29:1649-1654.

Combes B, Markin RS, Wheeler DE, Rubin R, West AB, Mills AS, Eigenbrodt EH, Maddrey WC, Munoz SJ, Garcia-Tsao G, Bonner GF, Boyer JL, Luketic VA, Shiffman ML, Peters MG, White HM, Zetterman RK, and Carithers RL. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999;30:602-605.

Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, Lamy P, and Murray A. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999;68(12):1912-1914.

Rubin DC, Zhang H, Qian P, Lorenz RG, Hutton K, and Peters MG. Altered enteroendocrine cell expression in T cell receptor alpha chain knock out mice. Microscopy Research and Techniques 2000;51:112-120.

Peters Marion. Animal models of Autoimmune liver disease. Immunology and Cell Biology 2002:80, 113-116.

Marion G. Peters and Norah A. Terrault. Alcohol Use and Hepatitis C. Hepatology 2002:36: s220-225.

M.G. Peters, H.W. Hann, P. Martin, E. Jenny Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D.F. Gray, M. Sullivan, K. Kleber, R. EbrahimiS. Xiong, C. L. Brosgart, for the GS 00 461 study group. Adefovir Dipivoxil Alone or in Combination with Lamivudine in Patients with Lamivudine-Resistant Hepatitis B Virus Gastroenterology 2004: 26:91-101

Raymond T. Chung, M.D., Janet Andersen, Paul Volberding, Gregory K. Robbins, Tun Liu, Kenneth E. Sherman, Marion G. Peters, Margaret J. Koziel, Beverly Alston, Dodi Colquhoun, Tom Nevin, George Harb and Charles van der Horst, for the A5071 Study Team. A randomized, controlled trial of PEG interferon alfa 2a plus ribavirin versus interferon alfa 2a plus ribavirin for chronic Hepatitis C virus infection in HIV co-infected persons: the US AIDS Clinical trials Group A5071 study team. N Engl J Med. 2004 Jul 29;351(5):451-9

Kenneth E. Sherman, Paul Horn, Norah Shire, Susan Rouster, Marion Peters, Margaret Koziel, Raymond T. Chung, and the ACTG 5071/5091s Study Group. Viral Kinetic Modeling in HCV/HIV Coinfected Patients Treated with Pegylated Interferon and Ribavirin. Gatroenterology In press 2004.

C. Graham, A. Wells, T. Liu, K. E. Sherman, M. Peters, R. Chung, J. Andersen, and M. Koziel for the ACTG 5071 Study Team. Relationships between Hepatitis C Virus-Specific Immune Responses and Outcome of Treatment with Interferon and Ribavirin in HIV/HCV Coinfection submitted.

Marion Peters, Janet Andersen, Ray Chung, Margaret Koziel, Kenneth Sherman, and Ray Apple for the ACTG A5071 Protocol Team. DNA Polymorphisms in Inflammatory Mediators Affect Severity of Disease and Response to Therapy in Subjects Co-infected with HCV and HIV: ACTG A5071. In preparation.

1/15/05